Partnering & Investment

Company Vision

We believe we have the potential to re-establish the standard of care for both prevention and treatment of heart attack patients. Our patent positions surrounding impacts of hemorrhage in cardiology combined with our current and future product in development can fill much-depleted pharmaceutical pipelines. Yet, we are keenly aware of the immediate need for our products: they will save lives. We also realize that time to market of these life-saving drugs depends on our ability to attain investment funds and partners for development and commercialization. Accordingly, we prefer to partner early with investors and strategic development/commercialization partners to bring these products to market as soon as possible. Blockbuster markets are addressed and we anticipate short (accelerated) FDA approval. Please contact us should you have interest in learning more, as we can share more data under confidentiality.

Partnering and Licensing Opportunities

Most drugs currently on the market for heart attack patients are focused on preventing future heart attacks or on managing the damage once done. For example, anti-platelets such as aspirin reduce blood clot risk while statins stabilize atherosclerotic plaques. Beta-blockers, Ace inhibitors, and VCRAs generally make it easier for the heart to pump blood. Yet, none are designed to eliminate hemorrhage-induced damage to the heart, once a heart attack has happened. Indeed, preventing heart damage and enabling the heart to heal is of central importance in the field and we believe the future for therapeutic interventions. Furthermore, most cardiology drugs for heart attack patients are no longer under patent protection.

Our extensive line of products holds the promise not only to save lives, but also to fill pharmaceutical pipelines with highly effective block-buster, therapeutics. Please contact us should you have interest in learning more.

Investment Opportunities

Investors are important – to bring our life-saving therapeutics to those in need as quickly as possible. While we anticipate that the efficacy and known safety profiles of our leading therapeutics will justify relatively small trials and accelerated FDA approval, funding is still required. Multiple block-buster markets are addressed for the unmet needs our products fill.

Timing is everything though. We anticipate few funding rounds. Please contact us to learn more.

And remember: the life you save may be your own.